Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 3/20 | 0.66 |
| ▸ | CHRM1 | P11229 | 9/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.56 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.56 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.56 |
| ▸ | PPARG | P37231 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5119224 | 1.00 | P2RX7 (0.66) | P2RX7CHRM1KMT2AMEN1CHRM2 | |
| SCHEMBL5115009 | 0.89 | P2RX7 (0.63) | P2RX7CHRM1KMT2AMEN1CHRM2 | |
| SCHEMBL5120264 | 0.88 | P2RX7 (0.65) | P2RX7CHRM1KMT2AMEN1CHRM2 | |
| SCHEMBL5120267 | 0.88 | P2RX7 (0.65) | P2RX7CHRM1KMT2AMEN1CHRM2 | |
| SCHEMBL5120270 | 0.88 | P2RX7 (0.65) | P2RX7CHRM1KMT2AMEN1CHRM2 | |
| SCHEMBL5120174 | 0.87 | CHRM1 (0.59) | P2RX7CHRM1KMT2ACHRM2CHRM4 | |
| SCHEMBL5115577 | 0.84 | P2RX7 (0.69) | P2RX7CHRM1KMT2AMEN1CHRM2 | |
| SCHEMBL5118249 | 0.81 | P2RX7 (0.55) | P2RX7CHRM1KMT2AMEN1NPC1 | |
| SCHEMBL5114386 | 0.81 | MEN1 (0.54) | P2RX7CHRM1KMT2AMEN1NPC1 | |
| SCHEMBL5126889 | 0.79 | P2RX7 (1.00) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146612-A1 | Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | claimed |
| US-20080146612-A1 | Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
| US-20080146612-A1 | Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
| US-20080146612-A1 | Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
| EP-1844003-A1 | NOVEL BIAROMATIC COMPOUNDS, INHIBITORS OF THE P2X7-RECEPTOR | AstraZeneca AB (SE) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006080884-A1 | NOVEL BIAROMATIC COMPOUNDS, INHIBITORS OF THE P2X7-RECEPTOR | ASTRAZENECA AB (SE) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146612-A1 | Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor | P2RX2, P2RX1, ADORA1 | P2RX7 4/4885CHRM1 243/4885KMT2A 3400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.